Name

Iovance Biotherapeutics

Legal name

Iovance Biotherapeutics, Inc.

Website

https://iovance.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Cell Therapy Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Cell therapy
• Tumor infiltrating lymphocytes
• Autologous immunotherapy
• Oncology biopharmaceuticals
• Solid tumor treatments

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Amtagvi (lifileucel) Sales: One-time autologous TIL cell therapy for advanced melanoma. Revenue from commercial product sales to authorized treatment centers. FY2025 revenue: $263.5 million, up 60.6% year-over-year. Q1 2026 revenue: $60 million. List price: $563,000 (as of 2026).
2. Proleukin (aldesleukin) Sales: Acquired from Clinigen in May 2023, Proleukin is used as supportive care in TIL treatment regimens. Q1 2026 contributed $11 million in revenue. Distributed through specialty pharmacy partnerships globally.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Iovance develops, manufactures, and commercializes autologous tumor infiltrating lymphocyte (TIL) cell therapies for the treatment of solid tumor cancers. Its flagship commercial product is Amtagvi (lifileucel), the first FDA-approved one-time T-cell therapy for solid tumors, indicated for advanced melanoma. The company also sells Proleukin (aldesleukin) as supportive care used within the TIL regimen, and is advancing a pipeline extending the same TIL platform to NSCLC, endometrial, cervical, head and neck, and soft tissue sarcoma indications.

Product overview

Iovance Biotherapeutics is a commercial-stage biopharmaceutical company offering a portfolio of tumor infiltrating lymphocyte (TIL) cell therapies. The core commercial products are Amtagvi® (lifileucel), the first FDA-approved individualized T-cell therapy for solid tumors (advanced melanoma), and Proleukin® (aldesleukin), acquired to support the TIL treatment regimen. The company operates a pipeline-in-a-drug strategy with lifileucel being studied across multiple solid tumor indications (NSCLC, cervical, endometrial, sarcoma, HNSCC), alongside next-generation TIL therapies including genetically modified IOV-4001 (PD-1 knockout via TALEN®), IOV-5001 (IL-12 tethered), and LN-145 Gen 3 (accelerated 16-day manufacturing). All TIL therapies are manufactured at the company's centralized 136,000 sq ft Iovance Cell Therapy Center (iCTC) in Philadelphia using proprietary Gen 2 processes.

Differentiator

Problem solved

Functional benefit

Brands

• Amtagvi: FDA-approved tumor infiltrating lymphocyte therapy (lifileucel) for advanced melanoma. Product website: www.amtagvi.com
• Proleukin
• Iovance Cell Therapy Center (iCTC)
• IovanceCares

Products and services

• Amtagvi (lifileucel) One-time, tumor-derived autologous T-cell immunotherapy (TIL therapy) for adult patients with unresectable or metastatic melanoma previously treated with anti-PD-1 therapy and, if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. Manufactured at iCTC Philadelphia and administered at authorized treatment centers with NMA-LD lymphodepletion and IL-2 support.
• Proleukin (aldesleukin) Interleukin-2 (IL-2) therapy used as supportive care within the TIL treatment regimen to promote T-cell activity and persistence after TIL infusion. Acquired from Clinigen and distributed by Iovance through authorized treatment centers globally alongside Amtagvi.
• Lifileucel (LN-145) Investigational autologous TIL therapy being evaluated across multiple solid tumor indications beyond the approved advanced melanoma setting, supporting Iovance's pipeline-in-a-drug strategy.
• IOV-4001 (PD-1 knockout TIL) Genetically modified autologous TIL therapy with the PD-1 gene inactivated using TALEN gene-editing technology licensed from Cellectis, designed to restore T-cell ability to kill cancer cells by avoiding checkpoint inhibition.
• IOV-5001 (IL-12 tethered TIL) Next-generation IL-12 tethered TIL cell therapy designed to express IL-12 only upon antigen encounter within the tumor microenvironment and tether it to the cell membrane to avoid systemic toxicity, remodeling the tumor microenvironment into an immuno-supportive state.
• LN-145 Gen 3 (16-day manufacturing) Third-generation TIL therapy using Iovance's proprietary 16-day GMP manufacturing process to reduce vein-to-vein time between tumor sample collection and infusion for patients, currently being explored in clinical trials.
• IOV-3001 (modified IL-2 analog) Second-generation modified IL-2 fusion protein (modified aldesleukin fused to a humanized monoclonal IgG1K antibody) licensed from Novartis, designed to enhance TIL survival and cellular proliferation with a potentially better safety profile and less frequent dosing compared to Proleukin.

Quantifiable outcome

• 44-52% objective response rate in advanced melanoma (real-world data), versus 31% in original C-144-01 clinical trial
• +5 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core.

• InspiroGene by McKessoncoreChannel Partner/ Reseller/ Distributor · 15 October 2025Specialty pharmacy partnership for Amtagvi product distribution in the United States. InspiroGene manages product fulfillment, cold chain logistics for the temperature-sensitive autologous cell therapy, and reimbursement support services.
• Clinigen (Acquired Proleukin Rights)coreOEM/ Whitelabel/ Licensing Partner · 1 May 2023In May 2023, Iovance acquired worldwide rights to Proleukin (aldesleukin) from Clinigen to strengthen its T-cell immunotherapy programs for advanced melanoma patients. Proleukin is used as supportive care in TIL treatment regimens and is now distributed through Iovance's commercial infrastructure.
• CellectiscoreTechnology or Integration · 1 January 2020In January 2020, Iovance and Cellectis entered into a research collaboration and worldwide license agreement enabling Iovance to use certain TALEN gene-editing technologies to modify TIL for therapeutic use in several cancer types. Iovance has a preclinical pipeline of TALEN-edited TIL therapies including double-knockout programs. This partnership enables development of next-generation gene-edited TIL products like IOV-4001 (PD-1 knockout TIL).
• National Institutes of Health / National Cancer InstitutecoreStrategic or Co-development PartnerCooperative Research and Development Agreement (CRADA) with Dr. Steven Rosenberg for development of TIL therapy alone or in combination with other agents for metastatic melanoma, bladder, lung, breast, and HPV-associated cancers. Also includes TIL + anti-PD-1 combination clinical trial for melanoma treatment.
• Moffitt Cancer CentercoreStrategic or Co-development PartnerTIL + anti-PD-1 antibody combination therapy clinical trial in non-small cell lung cancer (NSCLC). Also conducting TIL clinical trial in adolescents and young adults with soft tissue sarcoma.
• The University of Texas MD Anderson Cancer CentercoreStrategic or Co-development PartnerTIL clinical trials to treat ovarian cancer, sarcomas, pancreatic cancer, and colorectal cancer. MD Anderson is one of the leading comprehensive cancer centers participating in Iovance's clinical development program.
• Yale UniversitycoreStrategic or Co-development PartnerTIL clinical trial to treat triple-negative breast cancer (TNBC). Academic collaboration advancing TIL therapy in an area of high unmet medical need.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Novartis: Major pharmaceutical company with Kymriah (first FDA-approved CAR-T) and licensing partner for Iovance's IOV-3001 modified IL-2 analog. Broad incumbent in cell therapy with established manufacturing capabilities and competing immuno-oncology portfolio.
• Merck & Co. Major pharmaceutical company with Keytruda (pembrolizumab) checkpoint inhibitor that Iovance combines with TIL therapy in TILVANCE-301. Broad incumbent and key strategic partner whose immuno-oncology franchise directly overlaps with Iovance's combination strategies.
• Bristol Myers Squibb: Major pharmaceutical company with established CAR-T franchises (Breyanzi, Abecma) and checkpoint inhibitor (Opdivo) competing in melanoma. Broad incumbent in cell therapy and immuno-oncology with overlapping patient populations and significantly larger resources.
• Gilead Sciences (Kite): Through its Kite Pharma subsidiary, Gilead markets Yescarta and Tecartus CAR-T therapies and is a leading cell therapy commercial organization. Broad incumbent with established autologous cell therapy manufacturing infrastructure and cell therapy experience applicable to Iovance's space.

Emerging players

• Cellectis: Clinical-stage gene editing company developing allogeneic CAR-T and TALEN-edited cell therapies. Iovance's technology partner for PD-1 knockout TIL (IOV-4001), making it a strategic peer and indirect competitor in gene-edited cell therapies.
• Lyell Immunopharma: Cell therapy company focused on solid tumor treatment with TIL and CAR-T programs, including technologies to prevent T-cell exhaustion. Emerging peer with overlapping technology focus on T-cell therapies for solid tumors.
• Allogene Therapeutics: Leading allogeneic CAR-T developer pursuing off-the-shelf cell therapies. Represents a potential competitive threat if allogeneic approaches succeed in solid tumors, contrasting with Iovance's autologous model.

Direct peers

• Turnstone Biologics: Clinical-stage biotech developing next-generation tumor-infiltrating lymphocyte (TIL) therapies for solid tumors, including selected TIL technology. Comparable as a TIL-focused competitor with similar autologous cell therapy development approach.
• Instil Bio: Clinical-stage biotechnology company developing autologous TIL therapies (ITIL-306 and ITIL-168) for solid tumors. Direct peer in TIL therapy development with similar manufacturing platform and target indications in melanoma and other solid tumors.
• Adaptimmune Therapeutics: Develops engineered T-cell therapies (SPEAR T-cells) for solid tumors using TCR technology. Directly comparable as a cell therapy company focused on solid tumor cancers with similar autologous manufacturing complexity and clinical development model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/iovancebio
• LinkedInlinkedin.com/company/iovance
• Facebookfacebook.com/Iovance-Biotherapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iovance Biotherapeutics